<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82407">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02032524</url>
  </required_header>
  <id_info>
    <org_study_id>LTS13769</org_study_id>
    <secondary_id>U1111-1147-3439</secondary_id>
    <nct_id>NCT02032524</nct_id>
  </id_info>
  <brief_title>NeoGAA Extension Study</brief_title>
  <acronym>NEO-EXT</acronym>
  <official_title>An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of NeoGAA In Patients With Pompe Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      Long-term safety and pharmacokinetics (PK) of neoGAA

      Secondary Objective:

      Long-term effect of neo-GAA on pharmacodynamic and exploratory efficacy variables
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study will be 6 years from the date the first patient enters the study.
      Each patient will continue with the study until the patient withdraws, the Investigator
      withdraws the patient, or the Sponsor terminates the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of adverse events (AEs) and treatment-emergent adverse events (TEAEs), including infusion-associated reactions (IARs) and deaths</measure>
    <time_frame>screening/baseline until year 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory assessments including hematology, biochemistry and urinalysis</measure>
    <time_frame>Monthly, from baseline until year 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>screening/baseline until year 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>every 6 months, from baseline until year 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-neoGAA immunoglobulin G (IgG) antibodies, and neutralizing antibody formation in IgG seropositive patients; anti-alglucosidase alfa IgG antibodies</measure>
    <time_frame>monthly, from baseline up to 6 months, then every 3 months until year 6; every 6 months from baseline until year 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>at 6 months, then yearly until year 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>at 6 months, then yearly until year 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>at 6 months, then yearly until year 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle glycogen content</measure>
    <time_frame>every 2 years, from baseline until year 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle magnetic resonance images for qualitative and quantitative muscle degenerative assessments</measure>
    <time_frame>every 2 years, from baseline until year 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Hex4</measure>
    <time_frame>every 6 months, from baseline until year 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma analyses of circulating mRNA and micro RNA</measure>
    <time_frame>every 6 months, from baseline until year 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum analyses of skeletal muscle RNA expression</measure>
    <time_frame>every 2 years, from baseline until year 6</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Glycogen Storage Disease Type II Pompe Disease</condition>
  <arm_group>
    <arm_group_label>neoGAA 5mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg every 2 weeks, intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neoGAA 10mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg every 2 weeks, intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neoGAA 20mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg every 2 weeks, intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GZ402666</intervention_name>
    <description>Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous</description>
    <arm_group_label>neoGAA 10mg/kg</arm_group_label>
    <arm_group_label>neoGAA 5mg/kg</arm_group_label>
    <arm_group_label>neoGAA 20mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Patients with Pompe disease who previously completed a neoGAA study. The patient and/or
        their parent/legal guardian is willing and able to provide signed informed consent, and
        the patient, if &lt;18 years of age, is willing to provide assent if deemed able to do so.

        The patient (and patient's legal guardian if patient is &lt;18 years of age) must have the
        ability to comply with the clinical protocol.

        The patient, if female and of childbearing potential, must have a negative pregnancy test
        [urine beta-human chorionic gonadotropin] at baseline.

        Exclusion criteria:

        The patient is concurrently participating in another clinical study using investigational
        treatment.

        The patient, in the opinion of the Investigator, is unable to adhere to the requirements
        of the study.

        The patient has clinically significant organic disease (with the exception of symptoms
        relating to Pompe disease), including clinically significant cardiovascular, hepatic,
        pulmonary, neurologic, or renal disease, or other medical condition, serious intercurrent
        illness, or extenuating circumstance that, in the opinion of the Investigator, precludes
        participation in the study or potentially decreases survival.

        The above information is not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 840006</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840010</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160-7321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840008</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840009</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840003</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056001</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208001</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250003</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250002</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276003</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276002</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 528001</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 826003</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>December 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
    <mesh_term>Glycogen Storage Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
